BIT
Director Trades
| Date | Director | Value |
|---|---|---|
| 7/4/25 | M. Hoy | $33,652 |
| 7/4/25 | M. Miller | $11,363 |
| 7/4/25 | R. Thomas | $12,600 |
Company News
Biotron Announces $2.5 Million Capital Raising to Fund Sedarex Acquisition
Biotron (ASX: BIT) has announced the acquisition of unlisted company Sedarex Limited, the owner of SedRx — a patented next-generation general anaesthetic — alongside a $2.5 million capital raising to fund the transaction and advance development programs. The acquisition delivers Biotron a late-stage clinical asset supported by US Food and Drug Administration (FDA) and European Medicines […]
Biotron’s Phase 2 trial confirms BIT225 HIV treatment potential
Biotron (ASX: BIT) has received further indications that its lead antiviral drug BIT225 is a potential candidate for the treatment of issues related to HIV. The company has informed shareholders that preliminary analyses of data from a Phase 2 clinical trial of BIT225-011 suggest that the primary objectives of the test program have been met. […]
Biotron buoyed by early trial success of BIT225 HIV-1 antiviral drug
Biotron (ASX: BIT) has obtained promising early results from a phase 2 clinical trial of the company’s lead antiviral drug BIT225. Preliminary analysis of trial data indicates BIT225 is having a unique effect beyond that seen with the current standard. It has also been assessed that the primary objectives of the trial have been met, […]
Biotron ruffles through its compound database in search of COVID-19 drug
The chase for effective COVID-19 treatments is well and truly on after biotech company Biotron (ASX: BIT) confirmed it intends to harness its proprietary compounds to develop a treatment for SARS-CoV-2, the coronavirus that causes the COVID-19 infection. Moreover, after completing initial assays on almost 50 different compounds, Biotron said its initial screening program has […]
Biotron’s BIT225 drug show to enhance body’s immune response to HIV
Biotron’s (ASX: BIT) lead candidate HIV-1 drug BIT225 has been shown to boost the body’s immune response to HIV by inhibiting viral protein Vpu, while also having an anti-viral effect. The company is presenting new data on BIT225’s positive impact on the body’s immune response against HIV this week at the 23rd International AIDS Conference. […]
Biotron presents further phase 2 trial results for HIV drug BIT225
Clinical stage company Biotron (ASX: BIT) is preparing to present results from its ongoing phase 2 trial into its lead BIT225 drug at the annual Conference on Retroviral and Opportunistic Infections (CROI) this week with new data showing that BIT225 “unmasks” HIV-infected cells that remain in the body despite treatment with approved anti-HIV-1 drugs. CROI is […]
Biotron to commence testing of compounds to destroy coronavirus
Australian clinical stage company Biotron (ASX: BIT) has announced it will commence the evaluation of “several promising compounds” which could target various strains of coronavirus, including the deadly 2019-nCoV creating a global health issue. Biotron has over 30 compounds in its proprietary small molecule compound library which have “good activity” against a range of coronaviruses, […]
Biotron rides wave of Phase 2 clinical trial success for HIV drug
Biotechnology company Biotron (ASX: BIT) is enjoying its moment in the sun on the back of a skyrocketing share price since news of a successful Phase 2 clinical trial for its BIT225 HIV drug hit the market last month. The company’s stock has soared over 950% since the release of trial results on 28 September, […]